NCT06489873 Lutein, Zeaxathin, and Fish Oil Supplementation
| NCT ID | NCT06489873 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Texas A&M University |
| Condition | Cognitive Performance |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-02-07 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-02-07 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months? Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation. Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density. Participants will be asked to take either a LZF supplement or placebo daily for 6 months.
Eligibility Criteria
Inclusion Criteria: * \<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire. Exclusion Criteria: * allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, MPOD between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.
Contact & Investigator
Karen M Beathard, PhD
PRINCIPAL INVESTIGATOR
Texas A&M University
Frequently Asked Questions
Who can join the NCT06489873 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Cognitive Performance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06489873 currently recruiting?
Yes, NCT06489873 is actively recruiting participants. Contact the research team at karen-beathard@tamu.edu for enrollment information.
Where is the NCT06489873 trial being conducted?
This trial is being conducted at College Station, United States.
Who is sponsoring the NCT06489873 clinical trial?
NCT06489873 is sponsored by Texas A&M University. The principal investigator is Karen M Beathard, PhD at Texas A&M University. The trial plans to enroll 80 participants.